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DBA/2J Mice Are Susceptible to Diabetic Nephropathy
and Diabetic Exacerbation of IOP Elevation
Ileana Soto1, Gareth R. Howell1,2, Cai W. John1, Joseph L. Kief1, Richard T. Libby3, Simon W. M. John1,2,4*
1 The Jackson Laboratory, Bar Harbor, Maine, United States of America, 2 The Howard Hughes Medical Institute, Bar Harbor, Maine, United States of America,
3 Departments of Ophthalmology and Biomedical Genetics, University of Rochester Medical Center, Rochester, New York, United States of America, 4 Department of
Ophthalmology, Tufts University of Medicine, Boston, Massachusetts, United States of America

Abstract
Some pathological manifestations of diabetes in the eye include retinopathy, cataracts and elevated intraocular pressure
(IOP). Loss of retinal ganglion cells (RGCs) in non-proliferative stages of diabetic retinopathy and small increases in IOP in
diabetic patients has raised the possibility that diabetes affects the development and progression of ocular hypertension
and glaucoma. The Ins2Akita mutation is known to cause diabetes and retinopathy on a C57BL/6J (B6) background by as early
as 3 months of age. Here, the impact of the Akita mutation on glaucoma was assessed using DBA/2J (D2) mice, a widely
used mouse model of ocular hypertension induced glaucoma. In D2.Ins2Akita/+ mice, the contribution of diabetes to vascular
permeability, IOP elevation, RGC loss, and glaucoma development was assessed. D2.Ins2Akita/+ mice developed a severe
diabetic nephropathy and early mortality between 6–8 months of age. This agrees with previous reports showing that the
D2 background is more susceptible to diabetes than the B6 background. In addition, D2.Ins2Akita/+ mice had vascular
leakage, astrocyte reactivity and a significant increase in IOP. However no RGC loss and no anterograde axonal transport
dysfunction were found at 8.5 months of age. Therefore, our data show that despite severe diabetes and an increased IOP
compared to controls, RGCs do not lose axon transport or degenerate. This may be due to a DBA/2J-specific genetic
modifier(s) that could provide novel and important avenues for developing new therapies for diabetic retinopathy and
possibly glaucoma.
Citation: Soto I, Howell GR, John CW, Kief JL, Libby RT, et al. (2014) DBA/2J Mice Are Susceptible to Diabetic Nephropathy and Diabetic Exacerbation of IOP
Elevation. PLoS ONE 9(9): e107291. doi:10.1371/journal.pone.0107291
Editor: Marta Agudo-Barriuso, Instituto Murciano de Investigación Biosanitaria-Virgen de la Arrixaca, Spain
Received June 13, 2014; Accepted August 12, 2014; Published September 10, 2014
Copyright: ß 2014 Soto et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper.
Funding: Funding was provided by NIH grants EY011721 (SWMJ) EY021525 (GRH), EY018606 (RTL), www.nih.gov; the Howard Hughes Medical Institute; and
Barbara and Joseph Cohen Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* Email: simon.john@jax.org

One study reported that short-term hyperglycemia, a feature of
diabetes, delayed axonal degeneration and RGC loss in a rat
experimental model of glaucoma [15]. A second study, also in a rat
experimental model, found that hyperglycemia increases apoptosis
in RGCs after induced IOP elevation [16]. It is still unclear if
diabetes affects glaucoma development or rate of progression, or if
any effects of diabetes on glaucoma vary with genetic constitution.
Mouse models for diabetes have shown some pathological
similarities to human diabetic retinopathy that include vascular
leakage, RGC loss, and glial changes [6,18,19,20]. Akita mice
have a single nucleotide substitution in the Insulin II gene
(Ins2Akita) that causes Type I diabetes. On the C57BL/6J (B6)
genetic background, the Akita mutation causes protein misfolding,
degeneration of the pancreatic ß cells, and consequently hyperglycemia [21]. B6.Ins2Akita mice also develop features of diabetic
retinopathy including loss of RGCs [6,18]. DBA/2J mice, a
commonly used genetic model of glaucoma, develop ocular
hypertension (IOP elevation) that ultimately leads to the death
of RGCs and optic nerve degeneration [22,23,24]. To study the
role of genetic background on diabetes development and
progression, the Ins2Akita mutation has been backcrossed into
the DBA/2J strain (D2.Ins2Akita/+ [25]). D2.Ins2Akita/+ mice
develop diabetes that is comparable to B6.Ins2Akita/+ mice, but

Introduction
Diabetes is the leading cause of blindness among adults between
20 to 74 years old in the United States [1,2]. Diabetic retinopathy
is characterized by vascular changes that lead to disruption of the
blood retinal barrier, microaneurysms, hemorrhages, and late
onset vascular proliferation [3,4]. Neuronal cell death at nonproliferative stages of diabetic retinopathy has also been observed
in human disease and experimental models [5,6,7,8]. Glaucoma is
characterized by the loss of retinal ganglion cell (RGCs) and
elevated intraocular pressure (IOP) is a major risk factor. In
addition, diabetic patients have higher IOP levels (+2 to 3 mmHg)
than non-diabetic people [9,10,11,12]. While this increase in IOP
is small, it has been suggested that the additional elevation in IOP
could increase the stress on RGCs and consequently the risk of
glaucomatous RGC loss [13].
Due to inconsistencies among epidemiological studies no clear
association of diabetes with glaucoma has been established [13]. In
fact, it has been suggested that early stages of diabetes may have
neuroprotective effects on RGCs in glaucoma [14,15]. Similarly,
two experimental studies inducing IOP elevation in diabetic rats
reported contradictory results in terms of diabetes effects on the
rate of progression of glaucomatous neurodegeneration [16,17].
PLOS ONE | www.plosone.org
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they develop a more severe diabetic nephropathy. Here we use
D2.Ins2Akita/+ mice to determine the contribution of diabetes to
diabetic retinopathy, IOP elevation, and RGC loss in this genetic
context.

ON at 4uC with the following primary antibodies: Nestin (1:200,
Chemicon); CD31 (PECAM1; 1:100, BD Pharmigen); MECA79
(1:50, Santa Cruz Biotechnology); and CD45 (1:100, BD
Pharmigen). After PBT washes (PBS, 0.5% Triton-X100) sections
were incubated in Alexa-conjugated secondary antibodies (1:1000,
Invitrogen) for 2 hrs, incubated with DAPI and mounted with
Aqua Poly/Mount.

Materials and Methods
Ethics Statement
The Jackson Laboratory animal care and use committee
approved the research presented in this manuscript. All experiments were performed in compliance with the ARVO statement
for use of animals in ophthalmic and vision research.

Assessment of glaucoma-relevant phenotypes
Slit-lamp bio-microscopy was used to track iris disease in all mice
and IOP measurements were performed as previously described
[28,29], in 10 mice per genotype (20 eyes) at 6 months and 19
mice per genotype (38 eyes) at 8.5 months of age. IOP elevation in
D2 mice is secondary to a depigmenting iris disease [30]. Slit lamp
examination at age 6 and 8.5 months in 10 mice per genotype and
age detected no differences in the iris disease of the diabetic
D2.Ins2Akita/+ mice when compared with D2.Ins2+/+ mice. Axon
counts were performed on retro-orbital optic nerve sections stained
with paraphenylenediamine (PPD) as previously described [23,31].
Briefly, using the software ImageJ 1.48, axonal counts were
performed by converting 20 images per optic nerve in one stack of
images, cropping the stack of images and counting axons
manually. Using Metamorph software, the total area counted as
well as the total optic nerve area were tracked and used for the
final count computation. The total counted area from the optic
nerve was .10% and the final count was calculated and expressed
as number of axons per optic nerve [22,23]. Ages and sample sizes
are detailed in the results and figure legends. A one-way ANOVA
was used for statistical analysis.
Axon transport analysis was performed on 4 (8 colliculi) 8.5month-old mice. Alexa Fluor 488-Cholera Toxin subunit B (CTB)
conjugate (Invitrogen) was injected into the vitreous as described
previously [32]. After 72 hours, mice were anesthetized and
euthanized via 4% paraformaldehyde cardiac perfusion. After
perfusion and submersed fixation with 4% paraformaldehyde,
brains were cryosectioned at 50 mm. Alexa Fluor 488 was
visualized using a fluorescence microscope (Zeiss). For image
quantification 8 pictures of each superior colliculus were taken and
intensity statistics were generated after surface segmentation using
the same threshold criteria (Imaris, Bitplane Scientific Software).
RGC quantification. Flat-mounted retinas were fixed in
buffered 4% PFA ON at 4uC with gentle rocking, washed with
PBT and incubated with rabbit polyclonal antibodies against
tubulin ß-III (TUBB3; 1:500, Sigma) and monoclonal GFAP
(1:500, DakoCytomation) for four nights at 4uC. After PBT
washes, the retinas were incubated in the respective Alexaconjugated secondary antibodies (1:1000, Invitrogen) for 2 hrs.
The retinas were washed in PBT and mounted in Aqua Poly/
Mount (Polysciences). For quantification of TUBB3+ RGCs, four
cuts were made in whole retinas to divided in 4 equal quadrants
and two digital images (350 mm6350 mm) were taken in the
peripheral retina in each quadrant. Manual counts were
performed using the cell counter plugin from the ImageJ 1.48
software. Number of retinas per group has been included in the
results and figure legends.

Mouse strain and husbandry
All mice were housed in a 14-hour-light/10-hour-dark cycle
under previously described conditions [26]. Mice heterozygous for
the Ins2Akita mutation on the DBA/2J genetic background
(D2.Ins2Akita/+) were obtained from the Jackson Laboratory (Stock
Number 007562). To produce experimental animals D2.Ins2Akita/+
mice were bred to DBA/2J mice. Siblings homozygous wild-type
for the Ins2 gene (D2.Ins2+/+) were used as controls and housed
with their diabetic littermates under the same conditions in the
same animal facility to minimize environmental differences. A
recent study has demonstrated that estrogen may protect female
Akita mice against diabetes [27]. Because hyperglycemia in
D2.Ins2Akita/+ female mice is limited and variable, only male mice
were used for the study. Experiments were performed in male
mice at 6 and 8.5 months old.

Assessment of diabetes-relevant phenotypes and
survival
To determine blood glucose levels, the AlphaTRAK blood
glucose monitoring system (Abbott) was used. A drop of blood
after tail puncture was used for the test in 10 mice per genotype
and age. Mice health condition was monitored weekly and body
weight for all mice was measured monthly from wean age. This
measurement offered an additional measure of disease progression
and also allowed monitoring of the general health of the mice. The
inability of a mouse to feed itself was established as a uniform
humane end point for all mice. DietGel Recovery (Clear H2O)
barrier packs were provided in addition to the pellet food to mice
that were reaching the established end point. When mice reached
their end point, they were euthanized via cervical dislocation or by
cardiac perfusion after anesthesia.
For the FITC-dextran amine vascular permeability assay 5 mice
(10 retinas) per genotype were injected in the tail vein with FITCdextran amine 70 KDa (FDA 100 mg/g; Invitrogen). After
30 min, mice were euthanized and whole eyes were fixed in 4%
paraformaldehyde overnight (ON) at 4uC. Whole retinas were
dissected and incubated with peroxidase (POD)-conjugated antiFITC (1:1000, Roche) and FITC tyramide amplification (TSA,
Perkin Elmer) was used for detection and amplification of the
FITC signal in the retina. After tyramide amplification, retinas
were incubated with GFAP antibody (Dako; 1:500) for four nights
at 4uC, followed by incubation with secondary antibody for 2 hrs.
Retinas were mounted with Aqua Poly/Mount. For quantitative
analysis of GFAP staining in the retina, 2 pictures were taken per
each of the 4 retinal quadrants in the retina periphery. GFAP
fluorescence labeling was analyzed with the imaging software
Imaris (Bitplane Scientific Software).
For the assessment of diabetic nephropathy, following cardiac
perfusion and post-fixation with 4% paraformaldehyde, kidneys
were dissected free, washed in PBS, weighed, and cryoprotected
with 30% sucrose ON at 4uC. 12 mm cryosections were incubated
PLOS ONE | www.plosone.org

Statistical Analysis
Statistical analysis was performed using a commercially
available statistical software package (JMP, version 10.0, USA).
The results were expressed as mean 6 SD. Statistical differences
were assessed using one-way analysis of variance (ANOVA); p,
0.05 was considered statistically significant. Experiments were
performed at least three times.
2
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Figure 1. Severe kidney dysfunction and premature death in D2.Ins2Akita/+ mice. (A) High and sustained blood glucose levels were found in
males D2.Ins2Akita/+ mice compared to their respective D2.Ins2+/+ littermates during the time of the study (n = 10 mice for each genotype and age; p,
0.001 for each age). (B) Severe loss of weight and wasting were found in D2.Ins2Akita/+ compared with D2.Ins2+/+ mice (n = 10 for each genotype and
age; p,0.001 each age). (C) Sudden and early death occurred in the diabetic D2.Ins2Akita/+ before 9 months (n.40 mice). (D) Kidney weight/body
weight ratio was significantly higher in D2.Ins2Akita/+ mice versus D2.Ins2+/+ (n = 10 kidneys). (E–F) Pathological changes associated with diabetic
kidney disease at 6.5 months. (E) Decreased immunoreactivity of nestin was evident in D2.Ins2Akita/+ glomerulus when compared with D2.Ins2+/+. No
differences in CD31 immunoreactivity in the glomerular capillary loop were found between diabetic and wild-type mice. (F) MECA79
immunoreactivity was observed in the glomeruli of D2.Ins2Akita/+ mice, but not in D2.Ins2+/+ glomeruli. The MECA79 immunoreactivity was coincident
with CD45 positive leukocytes (arrows) in these affected glomeruli. Non-specific green fluorescence in kidney tubules was observed. Scale bars: (E)
10 mm, (F) 30 mm.
doi:10.1371/journal.pone.0107291.g001

months of age. Consistent with previous reports [25], D2.Ins2Akita/
mice had significantly higher blood glucose levels than D2.Ins2+/
+
control mice (Fig. 1A; n = 10; p,0.001). However, at 6 and 8
months of age, D2.Ins2Akita/+ mice had significant weight loss
compared D2.Ins2+/+ controls (Fig. 1B; n = 10 for each genotype;
p,0.001 for each age). The significant weight loss was followed by
premature death of D2.Ins2Akita/+ mice by 9 months of age, with
only 15% surviving, compared to 88% of D2.Ins2+/+ control mice
(Fig. 1C; n = 40 for each genotype; p,0.001).

Results

+

D2.Ins2Akita/+ die prematurely, likely due to severe kidney
dysfunction
To assess the impact of DBA/2J (D2) genetic background on
diabetes-induced IOP elevation and RGC loss, cohorts of male
D2.Ins2Akita/+ and D2.Ins2+/+ control mice were established and
aged. Each cohort contained at least 40 mice. For each mouse, the
levels of glucose in the blood were measured at 3, 6 and 8.5
PLOS ONE | www.plosone.org
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body weight) was observed in D2.Ins2Akita/+ mice at 6 months of
age compared with aged-matched control mice (Fig. 1D; n = 10
for each genotype; p,0.001). At 6.5 months of age, immunoreactivity of nestin (a marker of podocytes in glomeruli) was greatly
reduced in the glomeruli of D2.Ins2Akita/+ mice compared to
D2.Ins2+/+ mice (Fig. 1E). Podocytes are essential for the function
of the kidney and so this confirms significant kidney dysfunction in
D2.Ins2Akita/+ mice. We also assessed inflammation as a second
marker of kidney dysfunction using immunoreactivity for
MECA79, an antibody that binds activated L-selectin ligands.
MECA79 was detected in the glomerular capillary loops of kidneys
from D2.Ins2Akita/+ mice and not present in D2.Ins2+/+ control
mice (Fig. 1F). The activation of L-selectin coincided with the
infiltration of CD45 positive leukocytes in the diabetic glomeruli
(Fig. 1F) suggesting a chronic inflammatory response in the
kidneys of D2.Ins2Akita/+ mice that was not observed in
D2.Ins2+/+. Therefore, our data add further evidence that severe
kidney dysfunction is a major cause of premature death in
D2.Ins2Akita/+ mice.

D2.Ins2Akita/+ mice show early stages of diabetic
retinopathy
To assess the impact of diabetes on retinal phenotypes in
D2.Ins2Akita/+ mice, retinal vascular permeability and reactive
gliosis, two known pathological and early hallmarks of diabetic
retinopathy [34] were assessed. Previously, it was shown that
blood-retinal barrier (BRB) breakdown and reactive gliosis occur
in B6.Ins2Akita/+ mice and that these changes preceded RGC loss
and neuroinflammation [6,18,35]. To determine the impact of
DBA/2J genetic background on BRB breakdown and reactive
gliosis, retinas from 6 months old D2.Ins2Akita/+ and D2.Ins2+/+
mice were examined after systemic injection of FITC-dextran
amine 70 kDa. In D2.Ins2Akita/+ mice, fluorescence signal was
observed leaking from vessels and into surrounding regions and
cells (Fig. 2A). Leakage of fluorescent tracer was observed in 80%
(8 out of 10 eyes) of the flat-mounted retinas from D2.Ins2Akita/+
mice. Leakage of the fluorescent tracer was never observed in
retinas from D2.Ins2+/+ mice (Fig. 2B; n = 10 retinas for each
genotype). To assess reactive gliosis, levels of glial fibrillary acidic
protein (GFAP), an astrocyte- and Müller glial cell-specific
intermediate filament protein that is commonly upregulated in
disease, was assessed. Expression of GFAP was significantly
increased in retinal astrocytes and Müller glia surrounding leaking
vessels in retinas from D2.Ins2Akita/+ mice compared to D2
controls (Fig. 2B–C). Together these data show that by six months
of age that the D2.Ins2Akita/+ mice have clear signs of early stages
of diabetic retinopathy.

Figure 2. Vascular leakage and astrocytes reactivity in D2.Ins2Akita/+ retinas. (A, B) To determine if the Akita mutation caused an
increase in vascular permeability in DBA/2J mice, systemic injections of
FITC-dextran amine 70 kDa were made into 6 month old D2.Ins2+/+ and
D2.Ins2Akita/+ mice. Astrocytes were labeled with GFAP (purple). While
FITC fluorescence signal was restricted to blood vessels in D2.Ins2+/+
retinas (n = 10), there was clear leaked fluorescence signal in the majority of D2.Ins2Akita/+ retinas (8 out of 10 retinas examined). (C) GFAP fluorescence intensity (purple) was significantly increased in D2.Ins2Akita/+
retinal astrocytes when compared with D2.Ins2+/+ retinas (p,0.05,
n = 10). Scale bar: 50 mm.
doi:10.1371/journal.pone.0107291.g002

Diabetes exacerbates IOP elevation in D2.Ins2Akita/+ mice
Hyperglycemia is associated with elevation of IOP in patients
with diabetes [36] and IOP is a major risk factor for glaucoma.
Male DBA/2J mice develop IOP elevation between 7 and 9
months of age [23,24]. Therefore, the impact of diabetes on IOP
elevation was determined using D2.Ins2Akita/+ mice. IOP measurements were made at 6 months of age (prior to IOP elevation in
male D2 mice, only males used in study see Methods) and 8.5
months of age (during IOP elevation). No significant difference in
IOP elevation was found between D2.Ins2Akita/+ (13.2262.47) and
D2.Ins+/+ (11.6263.57) mice at 6 months of age (Fig. 3). However,
IOP levels were significantly higher in the D2.Ins2Akita/+
(17.6064.30) mice at 8.5 months compared to D2.Ins+/+
(13.9064.66) mice (Fig. 3, p,0.001). This indicates that diabetes
phenotypes exacerbate IOP elevation in DBA/2J mice.

Given that D2.Ins2Akita/+ mice have severe albuminuria and
kidney dysfunction by 6 months of age [25], the development of
severe diabetic nephropathy and pyelonephritis have been
proposed to be contributors of the increased mortality in
D2.Ins2Akita/+ [33] but never fully determined. Therefore, the
kidneys of D2.Ins2+/+ and D2.Ins2Akita/+ mice were examined.
Significant kidney hypertrophy (determined by kidney weight/

PLOS ONE | www.plosone.org
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Figure 3. The Akita mutation increased IOP in DBA/2J mice. To determine if the Akita mutation caused an increase in IOP in DBA/2J mice, IOP
were recorded from D2.Ins2+/+ and D2.Ins2Akita/+ mice at 6 and 8.5 months old. No significant differences in IOP measurements were found between
diabetic D2.Ins2Akita/+ and D2.Ins2+/+ at 6 months of age (n = 20 eyes for each genotype; p = 0.106). However by 8.5 months diabetic D2.Ins2Akita/+
showed significant higher IOP levels when compared with wild type D2.Ins2+/+ (n = 38 eyes for each genotype; p,0.001).
doi:10.1371/journal.pone.0107291.g003

superior colliculus of D2.Ins2Akita/+ and D2.Ins2+/+ mice using the
fluorescent tracer Alexa Fluor 488-CTB. No significant differences
were observed between D2.Ins2Akita/+ or D2.Ins2+/+ mice indicating
that, by this measure, RGC axons appear to be functioning normally
(Fig. 5D–F).

D2.Ins2Akita/+ mice do not show RGC dysfunction and loss
Akita/+

On the B6 genetic background the Ins2
mutation causes
significant RGC loss by 3 months of age in some studies [6,18] and
by 6 months in others [37]. The vast majority of RGC loss due to
IOP elevation occurs in DBA/2J mice between 10–12 months of
age [23]. Since D2.Ins2Akita/+ are not generally viable past 9
months of age (Fig. 1), RGC loss was assessed in D2.Ins2Akita/+
mice at 8.5 months using an established method of counting
TUBB3+ RGCs [38]. At this age, based on RGC loss at 3 to 6
months of age in B6.Ins2Akita/+ mice, which have less severe
diabetes [6], there should be a long enough exposure to diabetes
phenotypes to kill RGCs. Furthermore, the additional IOP insult in
the D2 background, which is greater in D2.Ins2Akita/+ mice, would
be expected to exacerbate the demise of RGCs [23,24]. Despite this,
there was no detectable loss of RGCs in D2.Ins2Akita/+ mice at 8.5
months of age (Fig. 4).
To determine whether RGC axon integrity and function was
diminished in D2.Ins2Akita/+ mice, a well-established optic nerve
damage assessment protocol and an anterograde axon transport
assessment were used (see Methods). For optic nerve assessment,
optic nerve sections were stained using paraphenylenediamine
(PPD) that differentially stains sick and dying axons [23,31]. PPD
stained nerves were analyzed using a validated system for assessing
optic neuropathy [23,31]. PPD staining can also detect damage to
single axons. Thus, it can also reveal subtle differences in RGC
axon damage between D2.Ins2Akita/+ and D2.Ins2+/+ mice. Consistent with the data analyzing RGC somas (see above), there was no
optic nerve damage present in either D2.Ins2Akita/+ or D2.Ins2+/+
mice (Fig. 5A–C). This observation was confirmed by axon counting
(Fig. 5C). Anterograde axonal transport dysfunction is a measure of
RGC function and occurs prior to RGC axon degeneration in
glaucoma [39]. Anterograde axonal transport was examined in the
PLOS ONE | www.plosone.org

Discussion
The DBA/2J inbred mouse strain is widely used to study a
variety of human diseases particularly ocular hypertension and
glaucoma. DBA/2J mice have also been shown to be susceptible to
kidney dysfunction and disease [25,40]. As diabetes has been
suggested to be a risk factor for IOP elevation, glaucoma and
kidney disease we used male mice from the DBA/2J.Ins2Akita/+
strain to assess the impact of diabetes on retinal and optic nerve
phenotypes and kidney dysfunction. Our data show that D2.
Ins2Akita/+ mice die prematurely and this is likely due to a severe
kidney dysfunction, more severe than that observed in B6.
Ins2Akita/+mice. This confirms previous findings that the DBA/2J
genetic background harbors genetic loci that predispose DBA/2J
mice to kidney dysfunction. Several quantitative trait loci have
been identified previously [40] but the underlying genetic
variations remain unknown. The severity of the kidney phenotype
in DBA/2J.Ins2Akita/+ mice makes this strain an attractive model
for identifying specific genetic variations that underlie susceptibility to diabetic nephropathy.
Analysis of kidneys from male D2.Ins2Akita/+ mice showed a
significant renal hypertrophy that was accompanied by a decrease
in glomerular-specific nestin immunoreactivity at 6.5 months of
age. It has been shown that downregulation of nestin by podocytes
in the glomerulus [41,42], is correlated with apoptosis induction in
podocytes during diabetes-induced hyperglycemia [43]. Loss of
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diabetic kidneys suggesting a chronic inflammatory response.
Kidneys from D2.Ins2Akita/+ mice showed positive immunoreactivity for the MECA79 antibody, which recognizes the sulfated
form of L-selectin ligands in endothelial cells [45]. Sulfation of Lselectin ligands is necessary for the mediation of leukocyte
migration to tissues and lymph nodes [45]. In our study, infiltrated
leukocytes, positive for CD45, were observed in D2.Ins2Akita/+
glomeruli that were also positive for MECA79. Leukocyte
infiltration and activation of inflammatory pathways have also
been implicated in the pathology of diabetic nephropathy
suggesting a main role of inflammation in renal failure [46].
Although there is no evidence of causative correlation between
kidney disease and glaucoma, several genetic disorders such as
nail-patella syndrome (LMX1B), oculocerebrorenal syndrome
(OCRL) and mutations in the type IV collagen gene (COL4A1),
are associated with both development of nephropathy and
developmental glaucoma [47,48,49,50]. Due to the premature
death of D2.Ins2Akita/+ mice, we were not able to fully explore the
impact of severe diabetic nephropathy on DBA/2J glaucoma,
although no premature loss of RGCs was observed at 8.5 months
of age.
The Akita mutation has previously been shown to cause diabetic
retinopathy on a B6 background where loss of RGCs is evident as
early as 3 months of age [6,18,37]. Contrary to what has been
reported in the B6.Ins2Akita mouse, no loss of RGCs was found in
the D2.Ins2Akita/+ at 8.5 months of age, suggesting that the DBA/
2J strain is more resistant to diabetes-induced RGC death than the
C57BL/6J strain. D2.Ins2Akita/+ do however, show vascular
phenotypes commonly associated with diabetic retinopathy,
particularly vascular permeability and reactive gliosis. Increased
vascular permeability, fluid leakage, deficits in blood flow that lead
to hypoxia of retinal tissue, and vascular proliferation are among
the most common and diagnosed manifestations of diabetic
retinopathy [3,4]. Although it has been generally thought that
neuronal loss in the retina occurs as a consequence of physical
breaking of the retinal architecture by proliferative vessels, several
studies have shown early loss of RGCs in human and experimental
diabetic retinas [5,6,7,8]. Our data, showing vascular leakage but
no RGC loss support that at least in some cases, vascular
phenotypes precede RGC loss or appear in the absence of RGC
loss.
Unfortunately, because of the severe kidney phenotype, we were
not able to assess the affects of diabetes on glaucomatous optic
neuropathy as this occurs in DBA/2J mice after 9 months of age.
However, given that diabetic patients present higher IOP profiles
than non-diabetics [9,10,11], the D2.Ins2Akita/+ mice do survive
long enough to address whether the Akita mutation alters
susceptibility to IOP elevation, a major risk factor for glaucoma.
Similarly to what has been found in humans, the D2.Ins2Akita/+
mice have a significant increase in IOP at 8.5 months old when
compared with wild-type DBA/2J mice. Despite the increase in
IOP, coupled with the increase the severity of diabetic nephropathy, in D2.Ins2Akita/+ mice compared to D2.Ins+/+, no significant
differences were detected in ganglion cell loss or in early signs of
glaucoma progression including axonal transport. Although
several epidemiological studies have suggested diabetes as a risk
factor for glaucoma, other studies have not found any association
between both diseases [13]. These conflicting results could reside
in the different experimental approaches, diagnostics and population used for these studies. Further, these conflicting reports
suggest genetic susceptibility plays a major part in disease
outcomes, something supported by the differences in both kidney
and retinal outcome between the B6 and D2 strains.

Figure 4. The Akita mutation does not cause RGC death out to
8.5 months of age in DBA/2J mice. (A, B) To determine if the Akita
mutation leads to RGC loss in DBA/2J mice, retinas from 8.5 month old
D2.Ins2Akita/+ and D2.Ins2+/+ mice were stained for the RGC marker
TUBB3+. (C) TUBB3+ cell counts showed that there was no significant
difference in RGCs detected in retinas of D2.Ins2Akita/+ mice compared
with D2.Ins2+/+ mice (n = 8 retinas for each genotype; p = 0.138). Scale
bar: 30 mm.
doi:10.1371/journal.pone.0107291.g004

podocytes in diabetic nephropathy leads to proteinuria and renal
failure [44]. We also found evidence of activation of L-selectin
ligands by endothelial cells in the glomerular capillary loop of
PLOS ONE | www.plosone.org
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Figure 5. The Akita mutation does not result in early axon degeneration or axon transport deficiency in DBA/2J mice. Optic nerve
degeneration is a hallmark of glaucoma and optic neuropathies. To determine if the Akita mutation leads to RGC axon loss and optic nerve
degeneration in DBA/2J mice, optic nerves from 8.5 month old D2.Ins2Akita/+ and D2.Ins2+/+ mice was assessed using PPD staining (A, B). All of the
optic nerves examined from both diabetic and wild-type mice were categorized as having mild damage, which means there was no detectable (or
only a low level of damage) damage that is consistent with aged and genetically matched wild-type mice that do not develop glaucoma or diabetic
retinopathy. (C) Quantitative analysis of axon counts in 8.5 months old optic nerves showed no differences between D2.Ins2+/+ and D2.Ins2Akita/+
(n = 20 optic nerves for each genotype; p = 0.894). (D–F) Loss of axon transport is a sensitive and early sign of a glaucomatous insult to RGCs and/or
RGC dysfunction. To determine if the Akita mutation leads to disruptions in RGC axon transport in DBA/2J mice, intravitreal injections of a
fluorescently labeled tracer, CTB-488, were made into 8.5 month old D2.Ins2Akita/+ and D2.Ins2+/+ eyes. (D, E) the superior colliculi of 8.5 months old
D2.Ins2Akita/+ mice appeared to fill the same as age-matched D2.Ins2+/+ mice. (F) Quantification of the fluorescent intensity showed there was no
significant difference between D2.Ins2+/+ and D2.Ins2Akita/+ mice (n = 8 colliculi for each genotype; p = 0.428). Scale bar: (A, B) 50 mm, (D, E) 150 mm.
doi:10.1371/journal.pone.0107291.g005

We found that chronic diabetes in the DBA/2J mouse increases
IOP but does not accelerate the development of early glaucoma in
these mice. Also, early signs of glaucomatous RGC dysfunction,
such as anterograde axonal transport and axonal degeneration,
were not different between diabetic and non-diabetic DBA/2J
mice. Therefore, it remains unanswered as to whether diabetes
would be an additive stressor to later stage glaucomatous RGC loss
in DBA/2J mice or even neuroprotective. A recent epidemiological study suggested that early stages of diabetes could be
neuroprotective for glaucoma [14,15]. Similarly, an experimental
study in rat demonstrated neuroprotective effects of diabetes
during acute induction of IOP elevation [16]. However, other
studies have demonstrated that after optic nerve crush, DBA/2J
PLOS ONE | www.plosone.org

RGCs are more resistant to RGC death than C57BL/6 due to a
genetic locus [51,52], suggesting that a genetic factor independent
of diabetes may be responsible for the strain difference in RGC
susceptibility. Identifying such a factor would provide important
information for developing drug therapies for treating diabetic
complications and RGC loss.
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